The association of gadolinium-based contrast agents (GBCAs) with nephrogenic systemicfibrosis (NSF) has led to a heightened awareness towards patients` renal function. Whereasdetailed guidelines exist for the use of GBCAs in adult patients, best practice is less welldefined in children, especially in the very young. We aimed at identifying current practicewith regards to the use of GBCAs in children who undergo Cardiovascular MagneticResonance.
We conducted a worldwide survey among cardiac imagers with pediatric expertise. Thequestionnaire contained 21 questions covering the imagers` work environments, GBCAsused, monitoring of renal function, and a special emphasis was placed on the practice inneonates.
The survey yielded 70 replies. The single most commonly used GBCA was gadopentetatedimeglumine 34/70 (49%). Among the respondents, the choice of GBCA was moreimportantly based on availability 26/70 (37%) and approval by a pharmaceutical licensingbody that most closely reflects the indication 16/70 (23%) than image quality 7/70 (10%) andside effect profile 8/70 (11%). 55/70 (79%) of respondents performed scans in neonates